Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab plus methotrexate in very early inflammatory arthritis
NL-OMON28713Recruiting
- Sponsor
- Department of Rheumatology, Medical University of Vienna
- Start
- Oct 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of infliximab and methotrexate in autoimmune arthritis and rheumatoid arthritis (RA) (3 arms), sponsored by Department of Rheumatology, Medical University of Vienna. Primary endpoint: Clinical remission at end of infliximab therapy. Started Oct 2007; status: recruiting.
02
Drugs
infliximabmethotrexate
03
Conditions
autoimmune arthritisrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON28713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28713.